Primer probe combination for detecting plasmodium vivax based on RPA (recombinase polymerase amplification), detection kit and application
By combining RPA constant temperature amplification technology and lateral flow chromatography test strips, a specific primer probe combination is designed to solve the problems of complex, time-consuming and costly operation of Plasmodium vivax detection, achieving rapid, simple and low-cost High sensitivity and specific diagnosis, suitable for on-site use at the grassroots level.
Patent Information
- Application Number
- CN202411451264.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-17
- Publication Date
- 2024-12-03
AI Technical Summary
Among the existing malaria diagnosis methods, the nucleic acid detection operation for Plasmodium vivax is complex, time-consuming and costly. The existing immune test strips cannot distinguish between Plasmodium vivax is from other malaria parasites, and the sensitivity of low-density infection is low, making it difficult to Meet the needs of rapid diagnosis at the grassroots site.
Using the detection method based on the combination of RPA constant temperature amplification technology and lateral flow chromatography test strips, a specific primer probe combination was designed, and the SSU rRNA gene of Plasmodium vivax was rapidly amplified under constant temperature conditions by using the recombinase polymerase amplification technology. Testing is carried out in combination with colloidal gold side flow chromatography test strips to achieve rapid and simple diagnosis.
It has achieved high sensitivity and specific detection of Plasmodium vivax. It has a short detection time, no special instruments and professional technology required, suitable for on-site use, low cost, suitable for rapid diagnosis at the grassroots level, and has a sensitivity and specificity of 100.00%.
Smart Images

Figure CN119061172A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological detection, and specifically relates to a primer-probe combination, a detection kit and an application thereof for detecting Plasmodium vivax based on the combination of RPA isothermal amplification technology and lateral flow chromatography test paper. Background Art
[0002] Malaria is a vector-borne infectious disease that seriously endangers human health and is widely prevalent in tropical and subtropical developing countries. Although the malaria epidemic has been brought under control to a certain extent after years of efforts, the global malaria situation remains severe.
[0003] At present, the commonly used methods for malaria diagnosis are: traditional etiological diagnosis represented by microscopy; immunological diagnosis represented by immunochromatographic test strips (ICT); and nucleic acid detection represented by PCR. Microscopy has the advantages of high detection rate, ability to distinguish worm species, identification of worm density, and low price, but it also has the disadvantages of being time-consuming and labor-intensive, requiring high professional skills, and easy to miss low-density infections. The advantages of immunochromatographic test strips are simple operation, short time consumption, intuitive and clear judgment, and no reliance on special instruments and professional technical experience. At present, a variety of immunological test strips for malaria diagnosis have been launched and widely used in laboratories and fields, such as CareStart, Wondfo, BinaxNOW, etc. However, these products can only distinguish between malignant malaria and non-malignant malaria, and cannot distinguish between the other three human malarial parasites (Plasmodium vivax, P. ovale, and P. malariae). At the same time, they have low sensitivity for samples with low-density infections, which brings inconvenience to diagnosis at the grassroots level, and is not conducive to the symptomatic treatment of patients and the timely formulation and implementation of epidemic control strategies. In recent years, nucleic acid testing has been widely used in the detection of various pathogens. Further developed technical tests such as real-time fluorescence PCR, nested PCR, and multiplex PCR have high sensitivity and specificity and can distinguish between insect species. However, the disadvantage is that the detection process is time-consuming, must rely on expensive instruments, has high technical requirements for operators, and is not suitable for field application.
[0004] In recent years, nucleic acid isothermal amplification technology has developed rapidly. Compared with traditional PCR technology, isothermal amplification technology enables nucleic acid to be amplified under constant temperature conditions, getting rid of expensive thermal cycle experimental instruments, and can achieve exponential amplification of target fragments in a short time, making nucleic acid amplification detection under various non-laboratory conditions a reality, especially suitable for field applications. Among various isothermal amplification technologies, recombinase polymerase amplification technology (RPA) is based on the T4 phage nucleic acid replication mechanism, which can achieve rapid and specific amplification of nucleic acids under constant temperature conditions (37℃~42℃), and can amplify nucleic acids to detectable levels within 20 minutes, with high sensitivity and specificity. RPA combined with colloidal gold lateral flow dipstick (LFD) has the advantages of sensitivity, specificity, simple operation, rapidity, and the ability to observe the test results with the naked eye. RPA-LFD has been used for the detection of various parasites such as schistosomiasis, Babesia, Cryptosporidium, and Trichinella, and has broad application prospects. Summary of the invention
[0005] In view of the above technical problems in the prior art, the present invention provides a detection method based on the combination of RPA isothermal amplification technology and lateral flow chromatography test paper, a primer probe combination, a detection kit and applications thereof for detecting Plasmodium vivax. The primer probe combination and detection kit based on RPA for detecting Plasmodium vivax are intended to solve the technical problems of the existing Plasmodium vivax nucleic acid diagnosis, which is complex, time-consuming and costly.
[0006] The present invention provides a primer and probe combination for detecting Plasmodium vivax based on RPA. The primer and probe combination is designed according to the Plasmodium vivax SSU rRNA gene sequence, the upstream primer nucleotide sequence is shown in SEQ ID NO: 1, the downstream primer nucleotide sequence is shown in SEQ ID NO: 2, and the probe nucleotide sequence is shown in SEQ ID NO: 3.
[0007] Furthermore, Biotin was modified at the 5' end of the downstream primer, FAM and C3Spacer were modified at the 5' and 3' ends of the probe, respectively, and dSpacer was modified at a position 15 nt away from the 3' end of the probe.
[0008] The details are as follows:
[0009] Upstream primer nucleotide sequence: 5'-TGTTGCAGTTAAAACGCTCGT-3'
[0010] Downstream primer nucleotide sequence: 5'-Biotin-GCTTTGAACACTCTAATTTACTCAAAG-3'
[0011] Probe nucleotide sequence: 5'-6-FAM-ATCGATATTTTAAGCAACGCTTCTAGCTTAAT / dSpacer / CCACATAA CTGATA-C3 Spacer-3'.
[0012] Biotin is biotin, and FAM is fluorescein, which are used as probe molecules for colloidal gold nucleic acid test strips to identify capture. C3 Spacer is a polymerase extension blocking group, and dSpacer is a base-internal nucleotide analog that replaces nucleotides. It is introduced into the oligonucleotide sequence as a spacer modification. The purpose of C3 Spacer is to block nucleic acid amplification, and dSpacer is the cleavage site of the nuclease Nfo. Only when the probe can bind to the amplification template will the THF residue at the dSpacer site be cleaved by the Nfo enzyme, and then continue to amplify to produce an amplification product modified by FAM and Biotin at both ends.
[0013] The present invention also provides a kit for detecting Plasmodium vivax based on RPA, comprising a lateral flow chromatography test paper for detecting RPA amplification results, wherein the lateral flow chromatography test paper comprises a sample pad, one end of the sample pad is tightly connected to one end of a colloidal gold pad containing a colloidal gold labeled probe, the other end of the colloidal gold pad is tightly connected to one end of a cellulose membrane, the other end of the cellulose membrane is tightly connected to one end of an absorbent pad, the colloidal gold labeled probe is composed of a streptavidin probe (SA) labeled with colloidal gold that can form a receptor-ligand specific binding with biotin labeled with a downstream primer; a detection line is arranged on the cellulose membrane near one end of the colloidal gold probe pad, which is composed of an anti-fluorescein antibody that can specifically bind to the probe labeled fluorescein, and a quality control line is arranged on the cellulose membrane between the detection line and the absorbent pad, and the quality control line is composed of an anti-streptavidin antibody that specifically binds to the colloidal gold labeled probe.
[0014] Furthermore, the above-mentioned kit for detecting Plasmodium vivax based on RPA includes an RPA reaction system, which is composed of four parts:
[0015] 1) Lyophilized reagents, including recombinase, single-stranded DNA binding protein, polymerase, endonuclease nfo, dNTPs, and adenosine triphosphate; in the RPA reaction system, the final concentration of the recombinase is 200
[0016] ng / μL, the final concentration of single-stranded DNA binding protein is 508ng / μL, the final concentration of polymerase is 160ng / μL, the final concentration of endonuclease nfo is 50ng / μL, the final concentration of dNTPs is 4mM, and the final concentration of adenosine triphosphate is 5mM;
[0017] 2) a rehydration buffer, comprising a Tris buffer, creatine phosphate, creatine kinase, dithiothreitol, and polyethylene glycol; in the rehydration buffer, the concentration of the Tris buffer is 100 mM, the concentration of creatine phosphate is 100 mM, the concentration of creatine kinase is 200 ng / μL, the concentration of dithiothreitol is 10 mM, and the concentration of polyethylene glycol is 0.1092 g / ml;
[0018] 3) a reaction initiator, magnesium acetate (MgOAc), wherein the concentration of the magnesium acetate is 140 mM;
[0019] 4) The primer-probe combination described above.
[0020] Furthermore, the RPA amplification reaction system is as follows: 2.1 μL of 10 μM upstream and downstream primers, 0.6 μL of 10 μM probe, 29.5 μL of rehydration buffer, 2.5 μL of magnesium acetate, 2 μL of DNA template, and 11.2 μL of nuclease-free water, and the mixture is added to an amplification reaction tube containing the lyophilized reagent.
[0021] The present invention also provides a method for using a kit for detecting Plasmodium vivax based on RPA, comprising the following steps:
[0022] a. DNA extraction: Use a blood DNA extraction kit to extract DNA from the patient's blood sample;
[0023] b.RPA amplification: using the kit described in claim 5 to perform RPA amplification reaction on the extracted DNA; the reaction conditions of RPA amplification are as follows: after mixing the upstream and downstream primers, probe, rehydration buffer and nuclease-free water, add them to the reaction tube containing the lyophilized reagent, after complete dissolution, add the DNA template to be detected, centrifuge, drop magnesium acetate on the side wall of the reaction tube, centrifuge again, incubate the reaction tube in a 39°C metal bath for 4 minutes, take out the reaction tube, mix it upside down 3-5 times, centrifuge and incubate it in a 39°C metal bath for 8-15 minutes;
[0024] c. LFD detection: After the reaction is completed, the reaction solution is dripped onto the lateral flow chromatography test paper for detection.
[0025] Determine whether the patient is infected with Plasmodium vivax based on the band display on the test paper detection line and the quality control line.
[0026] Specifically, the cellulose membrane can be a nitrocellulose membrane (NC membrane) or a cellulose acetate membrane or a mixed membrane; the colloidal gold probe pad can be a glass fiber membrane or a polyester fiber membrane; the sample pad can be glass fiber or polyester fiber or a mixed fiber; the absorbent pad is made of absorbent material, such as absorbent paper.
[0027] Specifically, the width of the cellulose membrane is controlled to be 20-30 mm; the width of the water absorbent pad is 20-40 mm; the width of the colloidal gold probe pad is 5-10 mm; and the width of the sample pad is 10-40 mm.
[0028] Furthermore, the working concentration of the anti-fluorescein antibody on the test line is 0.1-2.0 mg / mL, and the spraying amount is 0.5-1 μL / cm; the working concentration of the rabbit anti-streptavidin antibody on the quality control line is 0.1-2.0 mg / mL, and the spraying amount is 0.5-1 μL / cm; the working concentration of the colloidal gold-labeled streptavidin probe (in terms of protein concentration) is 10-60 μg / mL, and the spraying amount is 40-50 μL / cm.
[0029] Furthermore, a back plate for supporting is arranged on the back of the lateral flow chromatography test paper, and the material of the back plate can be selected in various ways, and can be a plastic plate, such as a polyvinyl chloride plate (PVC) and the like.
[0030] The present invention discloses a primer and probe combination for detecting Plasmodium vivax based on RPA, the combination comprises an upstream primer, a downstream primer and a probe designed according to the Plasmodium vivax SSU rRNA gene sequence, the probe is an oligonucleotide blocked at the 3' end, and a non-terminal position also contains a nuclease nfo recognition site; the 5' end of the probe is labeled with a first marker, the 5' end of the downstream primer is labeled with a second marker, and the first marker and the second marker are specifically bound to different molecules. In the present invention, the two markers are biotin and fluorescein (6-FAM), respectively.
[0031] In the detection process of the present invention, once the detected sample contains the Plasmodium vivax SSU rRNA template, it will be replicated and amplified in the RPA constant temperature amplification system, and the two ends of the amplification product contain biotin and fluorescein markers respectively.
[0032] The amplified product is detected by the lateral flow chromatography test paper of the present invention, wherein the test paper uses colloidal gold-labeled streptavidin as a detection probe and is attached to a colloidal gold probe pad. During the detection process, the re-dissolved colloidal gold-labeled probe can bind to the biotin labeled on the amplified Plasmodium vivax SSU rRNA nucleic acid fragment for receptor-ligand specificity to form a complex, which is chromatographed onto a cellulose membrane under capillary action.
[0033] The lateral flow chromatography test paper of the present invention fixes the anti-fluorescein antibody on the cellulose membrane to form a detection line. When the amplified nucleic acid fragment probe complex flows through the detection line, the anti-fluorescein antibody fixed on the cellulose membrane captures the fluorescein labeled on the nucleic acid probe complex, thereby forming a precipitation line (color ribbon) visible to the naked eye.
[0034] The present invention fixes an antibody that can specifically bind to the detection probe on a cellulose membrane as a quality control line. The colloidal gold labeled probe is streptavidin (SA), and the corresponding quality control line uses a rabbit anti-streptavidin polyclonal antibody. Regardless of whether the sample to be tested contains the amplified product of Plasmodium vivax SSU rRNA, a color band can always be formed at the quality control line position of the diagnostic test strip of the present invention, and the color band is a standard for determining whether the detection process is normal and whether the diagnostic test strip is deteriorated.
[0035] The immunochromatographic test strip of the present invention has the following advantages:
[0036] (1) The present invention is based on isothermal nucleic acid amplification technology and has high sensitivity and specificity for low-density infection: Laboratory assessment results show that the sensitivity of the kit for detecting Plasmodium vivax based on RPA of the present invention is
[0037] 100.00%, with a specificity of 100.00%.
[0038] (2) The detection method is simple. No special equipment or personnel training is required during the detection process. Non-professional technicians can operate it according to the instructions. The detection time is short and the results can be observed quickly in about half an hour. It is very suitable for on-site and grassroots use; it is suitable for rapid field detection.
[0039] (3) Good stability and easy storage. Low cost and easy industrial production. The present invention will play an important role in the diagnosis and treatment of malarial parasites and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The results of agarose gel electrophoresis of the reaction solution after RPA amplification of samples from four Plasmodium infected persons and healthy persons using the three sets of upstream and downstream primers and probe sets designed according to the Plasmodium vivax SSU rRNA gene sequence described in Example 1 of the present invention. Figure 1 -A is the electrophoresis result of the amplified product using primer and probe set 1; Figure 1 -B is the electrophoresis result of the amplified product using primer and probe set 2; Figure 1 -C is the electrophoresis result of the amplification product using primer and probe set 3. Figure 1 Lanes 1 and 2 in 1-A, 1-B, and 1-C are samples from patients infected with Plasmodium falciparum; lanes 3 and 4 are samples from patients infected with Plasmodium ovale; lanes 5 and 6 are samples from patients infected with Plasmodium vivax; lanes 7 and 8 are samples from patients infected with Plasmodium malariae; and lanes 9 and 10 are samples from healthy subjects.
[0041] Figure 2The front and longitudinal sections of the lateral flow chromatography test paper (LFD) for detecting RPA amplification results of the present invention are shown in FIG. 1 is a sample pad; 2 is a colloidal gold probe pad; 3 is a cellulose membrane; 4 is a water-absorbing pad; 5 is a detection line; 6 is a quality control line; and 7 is a back plate.
[0042] Figure 3 It is a schematic diagram of the interpretation of the lateral flow chromatography test paper (LFD) for detecting the RPA amplification results described in the invention.
[0043] Among them: 1 is the cellulose membrane; 2 is the MAX line (indicating the highest position of the sample liquid level); 3 is the sample pad; 4 is the quality control line C; 5 is the detection line T; A is a schematic diagram of a positive result; B is a schematic diagram of a negative result; C is a schematic diagram of an invalid result. DETAILED DESCRIPTION
[0044] The present invention is further explained below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention. After reading the present invention, various equivalent forms of modifications to the present invention by those skilled in the art all fall within the scope defined by the claims attached to this application.
[0045] Example 1 Design of primer probe
[0046] The invention provides a primer-probe combination, which is based on the recombinase polymerase isothermal amplification technology combined with lateral flow chromatography test paper to detect Plasmodium vivax. The SSU rRNA gene sequences of Plasmodium vivax are very similar to those of Plasmodium falciparum, Plasmodium ovale and Plasmodium malariae. In order to obtain Plasmodium vivax-specific primers and probes, the SSU rRNA gene sequences of Plasmodium vivax (GenBank X13926.1), Plasmodium falciparum, Plasmodium ovale and Plasmodium malariae are downloaded from GenBank, and the sequences are aligned using the gene alignment software DNAman to determine the conserved regions.
[0047] RPA is an emerging isothermal amplification technology. Currently, there is no primer design software specifically for this technology. Therefore, the specific amplification sequence is determined after sequence alignment, and the upstream and downstream primers and probes are designed using Primer Premier 5.
[0048] During the design, the hairpin structure and dimer formation of primers and probes were avoided. The length of the amplified product was controlled between 200-400 bp, the length of the upstream and downstream primers was between 30-35 nt, and the length of the probe was greater than 45 nt. At the same time, in order to display the amplified product in combination with the lateral flow chromatography test strip, Biotin was modified at the 5' end of the downstream primer, FAM and C3Spacer were modified at the 5' and 3' ends of the probe, respectively, and dSpacer was modified at a position 15 nt away from the 3' end of the probe. Based on the above principles, a total of 3 sets of primer-probe combinations were designed for Plasmodium vivax. The primer and probe sequences are shown in Table 1.
[0049] Table 1. Sequence list of upstream and downstream primers and probes
[0050]
[0051] Example 2 Establishment of RPA method and screening of primers and probes
[0052] This embodiment provides a method for detecting Plasmodium vivax based on RPA technology, and screens and obtains the most specific primers and probes for Plasmodium vivax. Specifically, the following steps are included:
[0053] 1. DNA extraction from blood samples containing malarial parasites:
[0054] Use the OMEGA blood DNA extraction kit to extract DNA from whole blood samples of patients containing Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and whole blood samples of healthy people, and follow the steps in the kit's instruction manual.
[0055] 2.RPA amplification:
[0056] The RPA reaction system was prepared according to Table 2. 2.1 μL of 10 μM upstream and downstream primers, 0.6 μL of 10 μM probe, 29.5 μL rehydration buffer (containing 100 mM Tris buffer (pH 7.5), 10.92% (w / v) polyethylene glycol, 10 mM dithiothreitol, 100 mM creatine phosphate, 200 ng / μL creatine kinase) and 11.2 μL nuclease-free water were mixed and then added to a reaction tube containing lyophilized reagents (components were 200 ng / μL Ecoli RecA protein (recombinase), 50 ng / μL Nfo (endonuclease IV), 508 ng / μL Ecoli SSB protein (single-stranded DNA binding protein), 160 ng / μL Bsu DNA polymerase (strand displacement DNA polymerase), 5 mM ATP, 4 mM dNTPs). After complete dissolution, 2 μL of the DNA to be detected was added. After a brief centrifugation, 2.5 μL of 140 mM magnesium acetate was added dropwise to the side wall of the reaction tube. After another brief centrifugation, the reaction tube was placed in a 39°C metal bath for 4 min, then taken out, inverted for 3-5 times, briefly centrifuged, and then placed in a 39°C metal bath for 13-15 min.
[0057] Table 2. RPA reaction system preparation table
[0058]
[0059]
[0060] 3. Detection of RPA amplification products:
[0061] After amplification, 10 μL of RPA reaction solution was taken for agarose gel electrophoresis, and the electrophoresis results were observed under ultraviolet light.
[0062] 4. Screening of primers and probes
[0063] The three sets of primers and probe combinations described in Example 1 were used respectively according to the RPA detection method established above to detect blood samples infected with Plasmodium vivax. The results showed that the three sets of primers and probes could all produce amplified bands of the expected size (Group 1: 210 bp; Group 2: 226 bp; Group 3: 252 bp).
[0064] Three sets of primers and probes were used to perform RPA detection on blood samples infected with Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax, Plasmodium malariae and healthy subjects. When the primer and probe combination of group 1 was used, only the RPA reaction solution amplification product of the blood sample infected with Plasmodium vivax showed a band of about 210 bp in size, and there were no bands (such as 100 bp) in the blood samples infected with Plasmodium falciparum, Plasmodium ovale, Plasmodium malariae and healthy subjects after RPA reaction amplification. Figure 1-A); when the primer and probe combination of group 2 is used, the RPA reaction solution amplification products of blood samples infected with Plasmodium falciparum, Plasmodium vivax, and Plasmodium malariae show a band of about 226 bp in size, and there are no bands in blood samples infected with Plasmodium ovale and healthy human samples after RPA reaction amplification (as shown in Figure 2). Figure 1 -B); When the primer and probe combination of group 3 is used, the RPA reaction solution amplification products of blood samples infected with Plasmodium falciparum, Plasmodium ovale, and Plasmodium vivax show a band of about 252 bp in size, and there are no bands after RPA reaction amplification of blood samples infected with Plasmodium malariae and healthy human samples (as shown in Figure 2A). Figure 1 -C).
[0065] Experiments have shown that only primers and probes in Group 1 can specifically detect Plasmodium vivax, so primers and probes in Group 1 were selected for subsequent detection experiments.
[0066] Example 3 Preparation of rabbit anti-streptavidin polyclonal antibody
[0067] This embodiment provides a method for preparing a quality control line (T line) antibody, which is suitable for lateral flow chromatography test paper (LFD) using colloidal gold-labeled streptavidin as a detection probe. Immunopreparation of rabbit anti-streptavidin polyclonal antibodies as a quality control line (T line) of multiple nucleic acid test paper.
[0068] 1. Streptavidin (SA) was purchased from Sangon Biotechnology.
[0069] 2. Dissolve 4 mg of streptavidin in 300 μL of physiological saline, add 600 μL of complete adjuvant, stir and emulsify, and inject subcutaneously behind the neck of 2 rabbits for immunization.
[0070] 3. After 30 days, 4 mg of streptavidin was dissolved in 500 μL of physiological saline, and 1000 μL of incomplete adjuvant was added and stirred for emulsification, and then injected subcutaneously behind the neck of the two immunized rabbits.
[0071] 4. After another 30 days, 4 mg of streptavidin was dissolved in 500 μL of physiological saline and injected subcutaneously behind the neck of the two immunized rabbits without adding an adjuvant.
[0072] 5. After another 20 days, 50 mL of pericardial blood was drawn from the two immunized rabbits, and the blood was centrifuged after coagulation to obtain antiserum, which was affinity purified using a G protein column to obtain polyclonal antibodies.
[0073] Example 4 Preparation of Lateral Flow Chromatography Test Paper (LFD) for Detecting RPA Amplification Results
[0074] This embodiment provides a method for preparing a lateral flow chromatography test paper (LFD) for detecting RPA amplification results. 1. Streptavidin (SA) was purchased from Sangon Biotechnology; anti-fluorescein antibody was obtained from
[0075] Purchased (Shanghai Jieyi Biotechnology Co., Ltd.); rabbit anti-streptavidin antibody was prepared according to the method of Example 3.
[0076] 2. Preparation of Streptavidin Colloidal Gold Probe Solution
[0077] (1) Preparation of colloidal gold by citric acid reduction method: Boil a 0.01% HAuCl4 (Shanghai Sinopharm Chemical Reagent Co., Ltd.) aqueous solution, add 2 mL of a 1% trisodium citrate aqueous solution under stirring, and continue boiling until the liquid turns dark red to obtain a colloidal gold solution.
[0078] (2) Preparation of streptavidin colloidal gold probe pad: adjust the pH value to 8.5 with 0.1M K2CO3 solution, add 10 μg / mL streptavidin per 100mL colloidal gold solution, stir for 1h, then add PVP4000 with a final concentration of 0.05%, stir for 30min, centrifuge at 10000rpm for 30min, discard the supernatant, wash the precipitate with 10mM, pH7.5 HEPES buffer, and redissolve it in 15mL of 10mM, pH7.5 HEPES buffer containing 15% sucrose by mass to obtain a streptavidin colloidal gold probe solution.
[0079] 3. 1200 μL of the streptavidin / colloidal gold probe solution was sprayed onto a glass fiber pad (Ahlstrom) with a length of 300 mm and a width of 80 mm, and dried at 37° C. for 0.5 h to obtain a streptavidin colloidal gold probe pad.
[0080] 4. Coating and assembly of rapid diagnostic nucleic acid test strips
[0081] like Figure 2 As shown, it is a front / longitudinal cross-sectional structure diagram of a lateral flow chromatography test strip for detecting RPA amplification results. The test strip consists of a sample pad ( Figure 2-1 )、Colloidal gold probe pad( Figure 2-2 ), nitrocellulose membrane ( Figure 2-3 ) and absorbent pads ( Figure 2 -4) The four parts are glued to the PVC backboard ( Figure 2 -7) on the composition; sample pad ( Figure 2-1 )、Colloidal gold probe pad( Figure 2-2 ), nitrocellulose membrane ( Figure 2-3 ) and absorbent pads ( Figure 2-4) are in close contact with each other in sequence; a detection line is provided on the nitrocellulose membrane ( Figure 2 -5)
[0082] and a quality control line ( Figure 2 -6). The preparation method of the test strip comprises the following steps:
[0083] (1) Coating of nitrocellulose membrane: Select a nitrocellulose membrane with a length of 300 mm and a width of 20 mm (Sartorius). Prepare the anti-fluorescein antibody to 0.5 mg / mL using 10 mM, pH 7.4 phosphate buffer (PBS), and coat it on the nitrocellulose membrane at the bottom edge Y = 8.0 mm using a BIODOT XZ1000 spotter to form a detection line ( Figure 2 -5); rabbit anti-streptavidin antibody was prepared to 1.0 mg / mL with 10 mM, pH 7.4 phosphate buffer and coated on the nitrocellulose membrane at the bottom edge Y = 12.0 mm using a spotter to form a quality control line ( Figure 2 -6); the coated nitrocellulose membrane was dried at 37°C for 2 h.
[0084] (2) Preparation of lateral flow chromatography test paper for detecting RPA amplification results: A PVC base plate with self-adhesive sticker on one side ( Figure 2 -7), and the treated nitrocellulose membrane ( Figure 2-3 ); The end of the membrane close to the quality control line is tightly attached to the absorbent pad (Millipore) ( Figure 2 -4); the end of the membrane close to the detection line is tightly attached to the colloidal gold probe pad ( Figure 2-2 ); the other end of the colloidal gold probe pad is tightly attached to the glass fiber sample pad (Shanghai Jie Ning Biotechnology Co., Ltd.) Figure 2-1 );
[0085] MAX line stickers on the surface of the junction between the sample pad, colloidal gold probe pad and nitrocellulose membrane;
[0086] Cut the test strips as needed, 4.0 mm wide and 8.0 mm long.
[0087] 5. Sample diluent: contains 10 mM PBS, 150 mM NaCl, pH 7.4.
[0088] Example 4 Usage and laboratory evaluation of the kit for detecting Plasmodium vivax based on RPA 1. Detection method of the kit for detecting Plasmodium vivax based on RPA of the present invention
[0089] (1) DNA extraction from blood samples containing malarial parasites (same method as in Example 2)
[0090] (2) Perform RPA amplification using the primer and probe combination of Group 1 in Example 2 (the method is the same as that of Example 2)
[0091] (3) LFD detection method: Take 5-10 μL of the RPA amplification reaction solution of the blood sample to be tested and drop it on the MAX line of the lateral flow chromatography test strip ( Figure 3-1 ) below the sample pad ( Figure 3-2 ) and slowly drip 3-4 drops (120-200 μL) of sample diluent. After 10 minutes, observe the nitrocellulose membrane ( Figure 3-3 )
[0092] The color development on the surface will be invalid if observed for more than 30 minutes.
[0093] 2. Result determination: Figure 3 Shown
[0094] (1) Quality control line C( Figure 3 -4) color development, detection line T( Figure 3 -5) color development, judged as positive for Plasmodium vivax infection ( Figure 3 -A);
[0095] (2) If only the control line C shows color, and the test line T does not show color, it is judged as negative, indicating that there is no Plasmodium vivax infection ( Figure 3 -B);
[0096] (3) If the control line C does not show color, regardless of whether the test line T shows color, it indicates an incorrect operation process or the kit has deteriorated and become ineffective. Figure 3 -C).
[0097] 3. Experimental results
[0098] The laboratory test results of the kit for detecting Plasmodium vivax based on RPA of the present invention are shown in Table 3. It can be seen that the sensitivity of the kit for detecting Plasmodium vivax based on RPA of the present invention is 100.0% and the specificity is 100.0%. The above test results show that the kit for detecting Plasmodium vivax based on RPA of the present invention can be used for the detection of Plasmodium vivax.
[0099] Table 3. Laboratory test results of the kit for detecting Plasmodium vivax based on RPA of the present invention
[0100]
Claims
1. A primer-probe combination for detecting Plasmodium vivax based on RPA, characterized in that: The nucleotide sequence of the upstream primer is shown in SEQ ID NO:1, the nucleotide sequence of the downstream primer is shown in SEQ ID NO:2, and the nucleotide sequence of the probe is shown in SEQ ID NO:
3.
2. The primer-probe combination for detecting Plasmodium vivax based on RPA according to claim 1, characterized in that: Biotin was modified at the 5' end of the downstream primer, FAM and C3 Spacer were modified at the 5' and 3' ends of the probe, respectively, and dSpacer was modified at a position 15 nt away from the 3' end of the probe.
3. A kit for detecting Plasmodium vivax based on RPA, comprising a lateral flow chromatography test paper for detecting RPA amplification results, wherein the lateral flow chromatography test paper comprises a sample pad, one end of the sample pad is tightly connected to one end of a colloidal gold pad containing a colloidal gold labeled probe, the other end of the colloidal gold pad is tightly connected to one end of a cellulose membrane, and the other end of the cellulose membrane is tightly connected to one end of a water absorbent pad, characterized in that: The colloidal gold labeled probe is composed of a colloidal gold labeled streptavidin probe that can form a receptor-ligand specific binding with biotin labeled with a downstream primer; a detection line is arranged on one end of the cellulose membrane close to the colloidal gold probe pad, which is composed of an anti-fluorescein antibody that can specifically bind to the probe labeled fluorescein; a quality control line is arranged on the cellulose membrane between the detection line and the water absorbent pad, and the quality control line is composed of an anti-streptavidin antibody that specifically binds to the colloidal gold labeled probe.
4. A kit for detecting Plasmodium vivax based on RPA according to claim 3, characterized in that: A back plate is provided on the back of the test paper to serve as a support.
5. A kit for detecting Plasmodium vivax based on RPA according to claim 3, characterized in that: Including an RPA response system, the RPA response system consists of four parts: 1) Lyophilized reagents, including recombinase, single-stranded DNA binding protein, polymerase, endonuclease nfo, dNTPs, and adenosine triphosphate; in the RPA reaction system, the final concentration of the recombinase is 200 ng / μL, the final concentration of the single-stranded DNA binding protein is 508 ng / μL, the final concentration of the polymerase is 160 ng / μL, the final concentration of the endonuclease nfo is 50 ng / μL, the final concentration of the dNTPs is 4 mM, and the final concentration of the adenosine triphosphate is 5 mM; 2) a rehydration buffer, comprising a Tris buffer, creatine phosphate, creatine kinase, dithiothreitol, and polyethylene glycol; in the rehydration buffer, the concentration of the Tris buffer is 100 mM, the concentration of creatine phosphate is 100 mM, the concentration of creatine kinase is 200 ng / μL, the concentration of dithiothreitol is 10 mM, and the concentration of polyethylene glycol is 0.1092 g / ml; 3) a reaction initiator, magnesium acetate, wherein the concentration of the magnesium acetate is 140 mM; 4) The primer-probe combination according to claim 1.
6. A kit for detecting Plasmodium vivax based on RPA according to claim 3, characterized in that The RPA amplification reaction system is as follows: take 2.1 μL of 10 μM upstream and downstream primers, 0.6 μL of 10 μM probe, 29.5 μL of rehydration buffer, 2.5 μL of magnesium acetate, 2 μL of DNA template, and 11.2 μL of nuclease-free water, and add the above mixture into an amplification reaction tube containing the lyophilized reagent.
7. The method for using the kit for detecting Plasmodium vivax based on RPA according to claim 3, characterized in that: The following steps are involved: a. DNA extraction: Use a blood DNA extraction kit to extract DNA from the patient's blood sample; b. RPA amplification: The extracted DNA is subjected to RPA amplification reaction using the kit described in claim 5; the reaction conditions of RPA amplification are as follows: the upstream and downstream primers, probe, rehydration buffer and nuclease-free water are mixed, added to the reaction tube containing the lyophilized reagent, and after complete dissolution, the DNA template to be detected is added, and after centrifugation, magnesium acetate is added dropwise to the side wall of the reaction tube, and after centrifugation again, Incubate the reaction tube in a 39°C metal bath for 4 minutes, then take out the reaction tube and mix it by inverting it 3-5 times. After centrifugation, incubate in a 39°C metal bath for 8-15 min; c. LFD detection: After the reaction is completed, the reaction solution is dripped onto the lateral flow chromatography test paper as described in claim 3 for detection, and the infection of Plasmodium vivax is determined based on the strip display of the test line and the quality control line of the test paper.
